Predictors of second primary cancers among patients diagnosed with lung cancer in the PLCO trial
Principal Investigator
Name
Omar Abdel-Rahman
Degrees
MD
Institution
Avicenna Oncology center
Position Title
Consultant and scientific director
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-417
Initial CDAS Request Approval
Nov 2, 2018
Title
Predictors of second primary cancers among patients diagnosed with lung cancer in the PLCO trial
Summary
A number of etiological factors which contribute to the development of lung cancer (e.g. smoking) might also predispose to the development of second primary cancers. Previous studies evaluating this research question were based on restrospectove registry-based analyses (e.g. SEER database). It is important to try to answer the same question in the context of prospectively collected dataset (like the PLCO trial dataset).
Aims
1. To determine the frequency of second primary cancers commonly developing among patients initially diagnosed with lung cancer.
2. To determine the factors associated with a higher risk of second primary malignancy development.
Collaborators
Dr. Omar Abdel-Rahman
Related Publications
-
Incidence and Mortality of Lung Cancer Among Never Smokers in Relationship to Secondhand Smoking: Findings From the PLCO Trial.
Abdel-Rahman O
Clin Lung Cancer. 2020 Sep; Volume 21 (Issue 5): Pages 415-420.e2 PUBMED -
Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis.
Abdel-Rahman O
Int. J. Clin. Oncol. 2020 Jan 9 PUBMED -
Pre-diagnostic body mass index trajectory in relationship to lung cancer incidence and mortality; findings from the PLCO trial.
Abdel-Rahman O
Expert Rev Respir Med. 2019 Aug 15 PUBMED -
Impact of Timeliness of Surgical Treatment on the Outcomes of Patients with Non-metastatic Non-small Cell Lung Cancer: Findings From the PLCO Trial.
Abdel-Rahman O
World J Surg. 2019 Jul 22 PUBMED